Skip to main content
Uncategorized

Crystax gains a capital increase of 2.1 million Euros

By 21 de May de 2004November 18th, 2020No Comments
< Back to news
 21.05.2004

Crystax gains a capital increase of 2.1 million Euros

Crystax Pharmaceuticals, a Spanish technology-based company devoted to drug discovery and design founded in 2002, has secured financial support from the companies Invertec, Najeti Capital (leading investor), and Barcelona Emprèn. In this operation, Nateji Capital will contribute 1.5 million euros, and Invertec and Barcelona Emprèn will provide 300,000 euros each. This financial agreement is the first of its kind in the biotech sector.


Crystax Pharmaceuticals is the leading company in Spain in the use of a technology platform for drug discovery and design. It carries out 3D resolution of the structures of pharmacological targets, which allows the identification of the fastest way to optimize a given drug. This new investment ensures the continuity of the company’s business plan for the coming years and the continuation of the research developed since its set up.

Crystax specializes in the development of anti-cancer drugs in its laboratory facilities at the Parc Cientific de Barcelona. The company focuses on the optimization of this process through reducing the development time and increasing its efficacy in initial phases. Crystax also collaborates with other companies in the sector by providing services based on in-house technology to facilitate drug discovery. At present, Crystax holds contracts with several leading pharmaceutical companies in Europe and in Spain, such as Almirall Prodesfarma and the Esteve Laboratories.

About Crystax Pharmaceuticals

Crystax Pharmaceuticals was set up in mid 2002 by the researchers Joan Aymami (Universitat Politècnica de Catalunya- Technical University of Catalonia), and Miquel Coll (Consell Superior d’Investigacions Científiques- Spanish Council for Scientific Research) after the discovery of molecules with anti-caner properties that act on DNA.

Furthermore, Crystax uses synchrotron particle accelerators, which produce light a million times brighter than any conventional x-ray source. At present, a synchrontron accelerator is being built in El Vallès (Barcelona), and is expected to become operational in 2008.

CIDEM. Generalitat de Catalunya